NCT01938612 - A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

269

Participants

Timeline

Start Date

September 12, 2013

Primary Completion Date

March 1, 2018

Study Completion Date

November 25, 2020

Conditions

Advanced Solid Tumors

Interventions

DRUG

MEDI4736

MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.

DRUG

tremelimumab

tremelimumab is administered by IV infusion every 4 weeks

Trial Locations (21)

333

Research Site, Taoyuan District

704

Research Site, Tainan City

10002

Research Site, Taipei

874-0011

Research Site, Beppu-shi

104-0045

Research Site, Chūōku

277-8577

Research Site, Kashiwa

362-0806

Research Site, Kitaadachi-gun

135-8550

Research Site, Kōtoku

737-0023

Research Site, Kure-shi

791-0280

Research Site, Matsuyama

464-8681

Research Site, Nagoya

541-8567

Research Site, Osaka

003-0804

Research Site, Sapporo

060-8648

Research Site, Sapporo

589-8511

Research Site, Sayama

565-0871

Research Site, Suita-shi

411-8777

Research Site, Sunto-gun

569-8686

Research Site, Takatsuki-shi

241-8515

Research Site, Yokohama

03080

Research Site, Seoul

135-710

Research Site, Seoul